The FDA on Friday said it approved Novo Nordisk’s popular weight-loss drug Wegovy to reduce the risk of severe heart issues in overweight or obese adults.
Wegovy gets FDA approval to reduce risk of heart issues in overweight adults
Read Next
- China and EU reassess trading relationship
- Walgreens (WBA) earnings Q2 2025
- Corsair closes sale of eurochange to Western Union
- Fake job seekers use AI to interview for remote jobs, tech CEOs say
- Pepperstone UK sees Revenues (£13.0M) and Profits (£9.9M) flat in 2024
- CySEC reaches €200k settlement with Colmex Pro
- RBI likely to infuse over Rs 4 lakh crore liquidity in FY26 as global headwinds mount, ET BFSI
